Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 26,625 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.59, for a total transaction of $95,583.75. Following the completion of the transaction, the chief financial officer now owns 86,773 shares in the company, valued at approximately $311,515.07. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of NASDAQ CERS traded up $0.43 during midday trading on Thursday, reaching $4.47. 837,382 shares of the stock were exchanged, compared to its average volume of 2,274,683. The firm has a market cap of $624.34 million, a price-to-earnings ratio of -8.60 and a beta of 1.19. Cerus Co. has a twelve month low of $2.71 and a twelve month high of $6.64. The firm has a 50-day simple moving average of $4.66 and a two-hundred day simple moving average of $4.51. The company has a quick ratio of 2.16, a current ratio of 2.55 and a debt-to-equity ratio of 1.01.
Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $20.92 million for the quarter, compared to analyst estimates of $20.90 million. Cerus had a negative return on equity of 112.64% and a negative net margin of 95.44%. Research analysts expect that Cerus Co. will post -0.44 EPS for the current fiscal year.
CERS has been the topic of several research reports. ValuEngine upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. BTIG Research started coverage on shares of Cerus in a research note on Wednesday, February 26th. They set a “buy” rating and a $7.00 price objective on the stock. BidaskClub cut shares of Cerus from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $7.33.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Further Reading: What are earnings reports?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.